{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-033020","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-04-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.742340+00:00","generated_at":"2026-06-16T10:49:18.976768+00:00","sec_items":["1.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nektar regains full rights to REZPEG from Lilly; plans Phase 2b in atopic dermatitis in 2023","bullets":["Lilly terminated license agreement at will; termination effective July 22, 2023; Nektar gets all rights back.","Nektar plans to initiate a Phase 2b study in moderate-to-severe atopic dermatitis in 2023 and explore other auto-immune indications.","Phase 1b data showed dose-dependent improvement over placebo in EASI, EASI-75, vIGA-AD, and Itch NRS with durable response.","Termination does not impact Nektar's cash guidance as milestone payments were not included in forecasts.","CEO Howard Robin expresses confidence in REZPEG's potential as a remittive therapy for atopic dermatitis."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-033020","json":"https://secwatch.observer/filing/0001213900-23-033020.json","markdown":"https://secwatch.observer/filing/0001213900-23-033020.md","text":"https://secwatch.observer/filing/0001213900-23-033020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/0001213900-23-033020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/ea177525-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T10:49:18.976768+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3b8e18ee55e26b51076199604f593df9fe9e7ebc","claim":"NEKTAR THERAPEUTICS terminated License Agreement with Eli Lilly and Company valued at termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald (effective 2023-07-22).","evidence_excerpt":"greement (the “Agreement”) with Eli Lilly and Company (“Lilly”), which Agreement was filed as an exhibit to Nektar’s Quarterly Report on Form 10-Q for the period ended September 30, 2017.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023033020/0001213900-23-033020-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Eli Lilly and Company"},{"label":"Value","value":"termination of all licenses and other rights granted by Nektar to Lilly with regard to the rezpegald"},{"label":"Effective","value":"2023-07-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}